Psoriasis is an autoimmune and inflammatory disease, which is estimated to affect 2–3% of the population in the world. PSORI-CM02 is an empirical formula of Chinese medicine optimized from Yin Xie Ling, which is widely used to treat psoriasis in China for decades. However, its antipsoriatic mechanisms are still not well understood. Here, we explored the therapeutic effects of PSORI-CM02 on psoriasis and its mechanisms of action in imiquimod-induced psoriasis-like mouse models and human HaCaT cells. In experiments in vitro, PSORI-CM02 significantly inhibited HaCaT cell proliferation in dose-dependent and time-dependent manners. Furthermore, it hindered the progression of HaCaT cell cycle and arrested HaCaT cells at G1 phase. On the other hand, our in vivo studies demonstrated that PSORI-CM02 dramatically reduced psoriasis area and severity index scores and lesion temperature in imiquimod-induced psoriatic mice. The antioxidative activities of glutathione, catalase, and superoxide dismutase were increased while oxidative activity of malonaldehyde was markedly decreased after treatments with PSORI-CM02. PSORI-CM02 also suppressed the mRNA expression of proinflammatory cytokines, including TNF-α, IL-6, and IL-17, and lowered their protein levels in the serum as well. In addition, PSORI-CM02 could reduce the expression of IKKα and NF-κB in psoriatic skin tissue. It also upregulated the proportion of CD4+ Foxp3+ regulatory T cells (Tregs) in both lymph nodes and spleens and promoted CD4+ CD25+ Treg proliferation in vitro. Taken together, our research demonstrated that PSORI-CM02 inhibited HaCaT cell proliferation by arresting them at G1 phase and alleviated systemic inflammation and psoriasis in mice via altering the oxidative/anti-oxidative status, tipping the balance between Th17 responsiveness and CD4+ Foxp3+ Treg generation, and suppressing the expression of proinflammatory cytokines as well as NF-κB signaling.

Keywords: psoriasis, inflammation, immunoregulation, regulatory T cell, PSORI-CM02

Abbreviations: CAT, catalase; DXM, dexamethasone acetate; GSH, glutathione; IMQ, imiquimod; MDA, malonaldehyde; PASI, psoriasis area and severity index; SOD, superoxide dismutase; Treg, regulatory T cell.
INTRODUCTION

Psoriasis is an autoimmune and inflammatory dermatologic disease, which affects about 2–3% of population in the world. Psoriatic pathology mainly includes thickening of epidermis, hyperproliferation of keratinocytes and parakeratosis in the epidermis with massive neutrophil infiltration in the dermis (1). Currently, the mechanisms underlying psoriasis have not been fully explored although it has been established that many factors, including genetic factors, environmental factors, immunological mechanisms, new blood vessel formation, lipid metabolism disorders, and unhealthy mentality, bear significant impacts on the occurrence of psoriasis (2). Nowadays, accumulating evidence suggests that patients with moderate or severe psoriasis may increase the risk of other diseases, including obesity, cancer, diabetes mellitus and the metabolic syndrome (3). Meanwhile, current treatments for psoriasis, such as topical therapies, phototherapies and conventional systemic therapies, are not completely satisfied by sufferers principally because of side effects and economic burden (4, 5).

During recent decades, Chinese herbal medicine, one of the traditional Chinese medicine that serves as a complementary and alternative medicine, has been used as popular strategies for treating psoriatic patients and aroused a remarkable and growing interest (6). Our previous researches have shown that Chinese herbal medicine can provide an effective therapy for psoriasis (7–10). PSORI-CM02, which was optimized based on Chinese herbal formula Yin-Xie Ling discovered by well-known professor Guo-Wei Xuan, is a novel formula of Chinese medicine for treating psoriatic patients and aroused a remarkable and alternative medicine, has been used as popular strategies for treating psoriatic patients and aroused a remarkable and growing interest (6). Our previous researches have shown that Chinese herbal medicine can provide an effective therapy for psoriasis (7–10). PSORI-CM02, which was optimized based on Chinese herbal formula Yin-Xie Ling discovered by well-known professor Guo-Wei Xuan, is a novel formula of Chinese medicine that has been used to effectively treat psoriasis during recent years. PSORI-CM02 consists of five Chinese herbs (Table 1), including *Rhizoma curcumae*, *Radix paeoniae rubra*, *Sarcandra glabra*, *Rhizoma smilacis glabrae*, and *Fructus mume*. Currently, PSORI-CM02 formula is further undergoing a randomized, double-blinded and placebo-controlled clinical trial for treating stable psoriasis vulgaris with a syndrome pattern of blood stasis in our hospital.

The objective of our current work was to reveal the antiproliferative properties of PSORI-CM02 in human HaCaT cells in vitro and the therapeutic effects of PSORI-CM02 on imiquimod-induced murine psoriasis as well as its mechanisms of action. We found that PSORI-CM02 suppressed HaCaT cell proliferation by hindering their cell cycle progression at G1 phase, inhibited the expression of proinflammatory cytokines and NF-κB signaling, upregulated CD4+ Foxp3+ regulatory T cells (Tregs) in vivo and promoted their in vitro expansion as well as reducing IL-17 production and ameliorating murine psoriasis.

MATERIALS AND METHODS

Animals

BALB/c mice (male, weighing 20 ± 2 g) were purchased from the Center of Laboratory Animals of Southern Medical University (Guangzhou, China). Mice were housed in a standard housing room with controlled temperature (22 ± 2°C), relative humidity (45–55%), artificial light (12 h light/dark cycle), and provided free access to food and water under a specific pathogen-free environment. The animal protocols were approved by the Animal Experimental Ethics Committee of Guangdong Provincial Hospital of Chinese Medicine.

Chemicals

Minimal essential medium (MEM), fetal bovine serum (FBS), and antibiotics (penicillin–streptomycin) were purchased from Gibco (Carlsbad, CA, USA). Dexamethasone acetate (DXM) was obtained from Shanghai Xinyi Pharmaceutical Factory (Shanghai, China). Imiquimod cream was obtained from Sichuan Mingxin Pharmaceutical Co., Ltd. (Sichuan, China). Eighteen chemical standards, including citric acid, gallic acid, 5-hydroxyethylfurfural, protocatechuic acid, Quercitrin, were obtained from Shanghai Aladdin Biological Technology Co., Ltd. (Shanghai, China) or Sigma-Aldrich (St. Louis, MO, USA).

Preparation of PSORI-CM02

Five Chinese herbal components (Table 1) contained in PSORI-CM02 formula were purchased from Guangdong Kangmei Pharmaceutical Company Ltd. (Guangdong, China). These herbs were extracted using distilled water and the extract was concentrated and stored for the future study.

Ultrahigh-Performance Liquid Chromatography (UHPLC) Analysis

Different batches of PSORI-CM02 formula were monitored for qualitycontrolpurposesbyUHPLCmethod.Briefly,PSORI-CM02 and 18 standards (Table 2) were dissolved with methanol–0.1%

| TABLE 1 | Constituents of PSORI-CM02. |
| --- | --- |
| Linean classification | Botanical origin | Ratio |
| Curcumae Rhizoma | Curcuma kwangsvensis S.G. Lee et C.F. Liang | 2 |
| Radix Paeoniae Rubra | Paeonia lactiflora Pall. | 3 |
| Rhizoma Smilacis Glabrae | Smilax glabra Roxb. | 5 |
| Mume Fructus | Prunus mume. (Sieb.)Siek.etZucc. | 2 |
| Sarcand Rheiherba | Sarcandra glabra (Thunb.)Nakai | 5 |

| TABLE 2 | Eighteen chemical constituents identified in PSORI-CM02. |
| --- | --- |
| Peak number | Formula | Identification |
| 1 | C₆H₈O₇ | Citric acid |
| 2 | C₇H₈O₆ | Gallic acid |
| 3 | C₇H₆O₅ | 5-Hydroxyethylfurfural |
| 4 | C₆H₈O₄ | Protocatechuic acid |
| 5 | C₇H₉O₅ | Neochlorogenic acid |
| 6 | C₆H₅O₃ | Oxyeconifolin |
| 7 | C₆H₇NO₃ | Amygdalin |
| 8 | C₇H₈O₃ | Chlorogenic acid |
| 9 | C₇H₈O₃ | p-Coumaric acid |
| 10 | C₇H₈O₄ | 5-D-cafeoylshikimic acid |
| 11 | C₇H₈O₅ | Isoferulic acid |
| 12 | C₇H₈O₅ | Neostigmin |
| 13 | C₇H₂O₂ | Astatin |
| 14 | C₇H₂O₂ | Neostoim |
| 15 | C₇H₂O₃ | Isoaustin |
| 16 | C₇H₂O₃ | Engletin |
| 17 | C₈H₁₀O₄ | Rosmarinic acid |
| 18 | C₈H₇O₃ | Quercitrin |
formic acid. Chromatographic separation was carried out with an Accela™ UHPLC system, which was comprised of a UHPLC pump and a PDA detector with a scanning from 200 to 400 nm and recorded at 214 nm. The HPLC conditions were set as following: Column: Kintex® C18, 150 mm × 2.1 mm, 2.6 µm particle size (Phenomenax, USA); Mobile phase components: A was water with 0.1% formic acid and B was methanol; Flow rate: 250 µL/min; injection volume: 10 µL; gradient: 0–45 min, linear gradient of 10–35% A, 45–50 min, 35–46% A, 50–60 min, 46–85% A.

Cell Culture
HaCaT cell line was purchased from American Type Culture Collection (Manassas, VA, USA). HaCaT cells were cultured in MEM (Gibico, USA) medium with 10% FBS (Gibico, USA) and 100 mg/mL and 100 IU/mL penicillin/streptomycin in a humidified atmosphere (5% CO₂, 37°C).

HaCaT Cell Proliferation Assays In Vitro

In vitro HaCaT cell proliferation was measured using MTT assays. Briefly, HaCaT cells in logarithmic growth were collected and transferred into a 96-well microplate. After 24 h, PSORI-CM02 was added to each well to make various concentrations (125, 250, 500, and 1,000 µg/mL, respectively) with six replicate wells per concentration. After further incubation for 24, 48, and 72 h, 10 µL of 5 mg/mL MTT was added to each well and incubated at 37°C for an additional 4 h. The supernatant then was removed and 100 µL of DMSO was added into each well. The absorbance (A value) was measured at the wavelength of 490 nm. The cell proliferation was presented as an OD value.

Cell Cycle Analysis
HaCaT cells were placed into six-well plates at 1.0 × 10⁶ cells/well and treated with various concentrations of PSORI-CM02 (125, 250, and 500 µg/mL) for 72 h. The cells were collected, rinsed twice with ice cold PBS and then fixed in 70% ethanol at 4°C overnight. The cells then were subject to a 30-min incubation with 250 µL of RNase A (100 µg/ml) at 37°C and propidium iodide (50 µg/ml, 500 µl) staining for 1 h. Stained cells finally were analyzed via a FACS-Calibur flow cytometer (BD Biosciences, San Jose, CA, USA). Three independent experiments were carried out.

Administration of Drugs
BALB/c mice were randomly grouped into six groups (n = 6 per group). The control groups were normal mice that were totally untreated. Vehicle and treatment groups, but not control groups, were given topical administration of imiquimod cream to induce psoriasis. Vehicle groups were administrated with distilled water while treatment groups of the mice were orally given DXM (10 mg/kg) or PSORI-CM02 (3, 6, and 12 g/kg, respectively), which was dissolved in distilled water, for a period of seven days. For in vitro experiments, control groups were the untreated cells in the media.

Imiquimod-Induced Psoriasis-Like Mouse Model
According to our previous studies, mice were topically administrated with a dose of 62.5 mg of 5% imiquimod cream applied to a shaved area (3 cm × 2.5 cm) on their back for seven consecutive days. The psoriasis area and severity index (PASI), which comprised parameters for skin erythema, scaling, and thickness, was employed to assess the condition of the psoriasis-like lesion on day 7. Parameters were scored independently on a scale from 0 to 4 according to the clinical signs, in which “0” represents none; “1” denotes slight; “2” means moderate; “3” depicts marked; and “4” indicates very marked clinically.

Measurement of Mouse Temperature by Infrared Thermal Image
The temperature of mice in each group was determined by the infrared thermal imager (Fluke, USA) in a quiet-state mode and photographs were analyzed by Smart View 3.2 software. Mice were then euthanized and blood samples were collected in the absence of anticoagulants and subjected to centrifugation (3,000 rpm) for 10 min to obtain serum for biochemical analyses.

Histological Analysis
The dorsal skin of the mice was harvested, fixed in 4% paraformaldehyde in PBS, and embedded in paraffin. Sections (5 µm) were then made and stained with hematoxylin and eosin (H&E) for histological analysis.

Measurements of Glutathione (GSH), Superoxide Dismutase (SOD), Catalase (CAT), and Malonaldehyde (MDA)
Skin tissues were homogenized in Tris-buffer (20 mM, pH 7.5) on ice using Ultra Turraks Homogenizer (IKA, Germany) and were subject to centrifugation (12,000 rpm) for 10 min. The supernatant was used to measure CAT and SOD activities and GSH and MDA levels. The protein concentration was measured using the Bradford method with BSA serving as a standard. The CAT and SOD activities and GSH and MDA levels were analyzed using commercial assay kits following the manufacturer’s instructions (Jiancheng Company, Nanjing, China).

Measurements of TNF-α, IL-6, and IL-17 via Enzyme-linked Immunosorbent Assay (ELISA) and RT-PCR
To evaluate the serum levels of TNF-α, IL-6, and IL-17, commercially available ELISA kits (eBioscience, USA) were utilized based on the instructions. The absorbance was read at 450 nm with a microplate spectrophotometer (Multiskan GO, Thermo Fisher Scientific, USA). Total mRNA was extracted from skin tissue with Trizol reagents and mRNA was then transcribed to cDNA. The primer sequences were shown in Table 3. The relative mRNA expression levels of cytokines versus GAPDH were measured using an ABI 7500 Fast Real-Time PCR System (Thermo Fisher Scientific, USA).

Western Blotting Analysis
Total protein samples from skin lesion tissues were acquired with RIPA lysis buffer followed by centrifugation (12,000 rpm and 5 min) in 4°C. Protein samples were subject to fractionation by SDS-PAGE and electro-transferred to PVD membranes. The
membranes were then blocked with 5% (w/v) skim milk in TBS-T containing 0.1% Tween-20 at room temperature for 2 h and subsequently incubated with primary antibody at 4°C overnight. Then, the membranes were washed three times using TBS-T and blotted with a corresponding secondary antibody conjugated with horseradish peroxidase for 1 h. Finally, the protein bands were detected using the enhanced chemiluminescence detection reagents. The band intensity was quantified using ImageJ software (NIH Image, Bethesda, MD, USA).

**CD4+ Foxp3+ Treg Quantification**

Lymph node and spleen cells from mice were prepared after treatments with PSORI-CM02. Cells were stained for surface markers with anti-CD4-PE/CD25-FITC Abs and then an intracellular marker with anti-Foxp3-APC using intracellular fixation/permeabilization kit (eBioscience, San Diego, CA, USA). CD4+ Foxp3+ Tregs were analyzed using a FACSAria III (BD, Biosciences). Since we found that only ~94% of CD4+ CD25+ T cells were FoxP3-positive (Figure S1 in Supplementary Material) in imiquimod-induced psoriatic mice, we quantified CD4+ Foxp3+ rather than CD4+ CD25+ cell population and defined the former as Tregs.

**CD4+ CD25+ Treg Proliferation In Vitro**

Splenic cells of C57BL/6J were harvested and CD4+ CD25+ T cells were purified by high-speed cell sorting via a FACSAria III (BD Biosciences). The purity of the cells was typically >96%. Then, the purified Tregs were labeled with 2 µM CFSE dye (Invitrogen, Karlsruhe, Germany) at 37°C for 10 min, and cultured in 96-well plates (2 x 10^5 cells/well) coated with anti-CD3/anti-CD28 Abs in complete RPMI-1640 media. PSORI-CM02 (125, 250, and 500 µg/mL) was added to the medium. After culturing for 4 days, cell proliferation was analyzed via FACS analyses.

**Statistical Analysis**

The data were statistically evaluated by a one-way analysis of variance followed by Dunnett's test and denoted as mean values ± SDs. Statistically significant differences were identified as either $P < 0.05$ or $P < 0.01$. All analyses were carried out through SPSS software (version 17.0, SPSS Inc., Chicago, IL, USA).

**RESULTS**

**Chemical Profiles of PSORI-CM02**

In order to control the quality of PSORI-CM02, we mainly detected eighteen chemical compositions of PSORI-CM02 by UHPLC analysis: citric acid, gallic acid, 5-hydroxymethylfurfural, protocatechuic acid, and so on (Table 2). UHPLC profiling also showed that PSORI-CM02 did not contain rapamycin and cyclosporin (Figure S2 in Supplementary Material).

**PSORI-CM02 Inhibits the Growth of HaCaT Cells**

MTT assay was performed to evaluate the antiproliferative effects of PSORI-CM02 on HaCaT cells in vitro. As shown in Figure 1, PSORI-CM02 at various concentrations ranging from 125 to 1,000 µg/mL significantly suppressed HaCaT cell proliferation at all time points (24, 48, and 72 h) in a dose-dependent manner.

**PSORI-CM02 Induces Cell Cycle Arrest in HaCaT Cells**

Since cell cycle progression plays an essential role in cell proliferation, flow cytometry was employed to investigate cell cycle distribution in HaCaT cells after treatments of the cells with PSORI-CM02. As shown in Figures 2A,B, there was no significant difference in HaCaT cell cycle progression at all phases between the group treated with low concentration of PSORI-CM02 (L) and control group. Augmenting PSORI-CM02 concentration to 125 to 1,000 µg/mL increased the frequency of the cells at G1 phase while reducing their percentage at S phase. Taken together, these studies revealed that PSORI-CM02 formula induced HaCaT cell cycle arrest at G1 phase in a dose-dependent manner.

**PSORI-CM02 Alleviates Clinical Symptoms and Reduces Skin Temperature of Imiquimod-Induced Psoriatic Mice**

Imiquimod-induced psoriasis-like mouse models were utilized to evaluate the antipsoriatic effects of PSORI-CM02. After treatments with imiquimod cream for three days, the clinical signs of psoriasis-like lesions, including skin erythema, scaling,
and thickness, appeared on the shaved dorsal skin, indicating that imiquimod-induced psoriasis-like mouse models were established successfully. Seven days after treatments with PSORI-CM02 or DXM, overall skin lesions were reduced and average PASI scores were decreased significantly compared with the vehicle group, as shown in Figure 3A. Mice treated with high doses of PSORI-CM02 appeared to be healthy except for mild psoriatic skin lesions. Histology demonstrated no liver and kidney injury in these mice (data not shown), suggesting that PSORI-CM02 is not toxic.

Since temperature assessment is one of the important indexes in inflammation, lesion temperature was measured in this study. As shown in Figure 3B, the psoriasis-like lesion temperature was increased significantly (\(P < 0.01\) vs. control group) seven days following administration of imiquimod cream while PSORI-CM02 treatments lowered the temperature remarkably compared to the vehicle group.

**Histological Evaluations**

Histological examinations via H&E staining were performed on the lesion skin seven days after treatments with PSORI-CM02. As depicted in Figure 3C, we found significant pathological changes characterized by increased acanthosis, hyperkeratosis of the epidermis, and abundant inflammatory infiltrates in the skin of imiquimod-induced psoriatic mice. Treatments with either DXM or PSORI-CM02 ameliorated the histological skin lesions, resulting in smoother epidermis, less parakeratosis, and reduced epidermal thickening.

**Effects of PSORI-CM02 on Antioxidative/Oxidative Levels of SOD, GSH, CAT, and MDA**

In this study, SOD, GSH, CAT, and MDA levels in the skin were measured by the corresponding assay kits seven days after treatments. As shown in Figures 4A–D, imiquimod-induced psoriatic mice produced lower levels of CAT, GSH, and SOD, but a higher level of MDA than did control mice. However, upon treatments with PSORI-CM02 at medium or high doses, the antioxidative activities of GSH, CAT, and SOD were elevated significantly (\(P < 0.05\) and \(P < 0.01\), respectively) compared to the vehicle group. Furthermore, PSORI-CM02 at the doses of 6 and 12 g/kg were shown to obviously reduce an MDA level in the skin.
FIGURE 3 | PSORI-CM02 ameliorates murine psoriasis. Shown are macroscopic appearance and the psoriasis area and severity index (PASI) scores of the skin lesions (A), the infrared thermal image of the skin tissue (B), and histological evaluation of the skin tissue via H&E staining (magnification 100×) (C) in imiquimod-induced psoriasis-like mice treated without or with PSORI-CM02. Data are presented as the mean values ± SDs (n = 6, *P < 0.05 and **P < 0.01 vs. control group, *P < 0.05 and **P < 0.01 vs. vehicle group).

Figure 3

Chen et al. PSORI-CM02 Formula Attenuates Murine Psoriasis

Frontiers in Immunology | www.frontiersin.org January 2018 | Volume 8 | Article 1767
tissue (both P < 0.01). These results suggested that PSORI-CM02 effectively regulated the oxidative/antioxidative balance toward a more favorable physiological equilibrium in imiquimod-induced psoriatic mice.

**PSORI-CM02 Suppresses mRNA and Protein Expressions of Proinflammatory Cytokines in Imiquimod-Treated Psoriatic Mice**

Effects of PSORI-CM02 on proinflammatory cytokine expression were also observed via ELISA and RT-PCR seven days after PSORI-CM02 treatment. As shown in Figures 4E–G, the levels of TNF-α, IL-6, and IL-17 in serum in imiquimod-induced psoriatic mice (vehicle) were increased compared to the control group. Although low doses of PSORI-CM02 did not achieve statistical significance, PSORI-CM02 at medium and high doses significantly reduced the levels of proinflammatory cytokines TNF-α, IL-6, and IL-17 in the serum compared to the vehicle group.

The mRNA expressions of TNF-α, IL-6, and IL-17 in skin tissue were also determined using RT-PCR. As shown in Figures 4H–J, the mRNA expressions of TNF-α, IL-6, and IL-17 were augmented after treatments with imiquimod (vehicle) while administration
PSORI-CM02 alters oxidative and antioxidative balance and suppresses proinflammatory cytokine expression. Effects of PSORI-CM02 on the activities of superoxide dismutase (A), catalase (B), glutathione (C), and malonaldehyde (D) in homogenized skin were determined using enzymatic activity assay kits while the levels of TNF-α (E), interleukin (IL)-6 (F), and IL-17 (G) in the serum of imiquimod-induced psoriasis-like mice were evaluated by enzyme-linked immunosorbent assay kits 7 days after PSORI-CM02 treatments. The mRNA levels of TNF-α (H), IL-6 (I), and IL-17 (J) in the skin were also determined using RT-PCR. Data shown are the mean values ± SDs (n = 6, *P < 0.05 and **P < 0.01 vs. control group, *P < 0.05 and **P < 0.01 vs. vehicle group).

of PSORI-CM02 at all three doses downregulated the mRNA levels of these cytokines compared with imiquimod-treated group without PSORI-CM02 (vehicle).

**PSORI-CM02 Inhibits NF-κB Signaling in the Skin with Psoriasis-Like Lesions**

Since PSORI-CM02 suppressed proinflammatory cytokine expression, we further explored the mechanisms underlying its antipsoriatic or anti-inflammatory effects. NF-κB signaling is a prominent therapeutic target for treating inflammatory diseases since aberrantly activated NF-κB signaling pathway contributes to inflammatory skin disorders. Thus, western blotting analysis was performed to evaluate the effects of PSORI-CM02 on NF-κB signaling pathway involving protein expression of NF-κB (P65) and IKKα. As shown in Figure 5, the expression of NF-κB and IKKα markedly increased after treatments with imiquimod compared to control group. In contrast, treatments with PSORI-CM02 markedly suppressed the expression of NF-κB and IKKα (P < 0.05 and P < 0.01, respectively) compared to the vehicle group.

**PSORI-CM02 Upregulates CD4+ Foxp3+ Tregs in Psoriatic Mice**

Regulatory T cells, a small subset of T cells, play an important role in preventing autoimmune diseases, including psoriasis. Therefore, we determined the frequency of Tregs in lymph nodes and spleens of psoriasis-like mice using FACS analyses seven days after treatments with PSORI-CM02, and the results were displayed in Figure 6. Treatments with either medium or high doses of PSORI-CM02 significantly augmented the frequency of CD4+ Foxp3+ Tregs in both lymph nodes and spleens compared with the vehicle group, although low doses of PSORI-CM02 only slightly increased the proportion of the Tregs.

**PSORI-CM02 Promotes CD4+ CD25+ Treg Cell Proliferation In Vitro**

Given that PSORI-CM02 could upregulate the frequency of CD4+ Foxp3+ Tregs in imiquimod-induced psoriatic mice in vivo, we determined its effects on Treg cell proliferation in vitro. FACS-sorted CD4+ CD25+ Tregs derived from naïve mice were labeled
with CFSE and stimulated with anti-CD3 and anti-CD28 Abs in the absence or presence of PSORI-CM02 for 4 days. As shown in Figure 7, PSORI-CM02 significantly promoted CD4+CD25+ Treg cell proliferation compared to the control group, suggesting that it can also expand Tregs in vitro.

DISCUSSION

Psoriasis is known as a chronic inflammatory dermatologic disease that affects around 2–3% of the general population (11). Although the causes for psoriasis are not fully understood, its most important pathological features include irregular epidermal hyperplasia, inflammatory infiltration and hyperplastic dermal blood vessels (12). Natural herbal medicine has been verified to be effective in preventing and treating psoriasis by attenuating aberrant proliferation and differentiation of keratinocytes (13, 14) and exerts anti-inflammatory, immunoregulatory (15, 16) and antiangiogenic effects (17). PSORI-CM02 formula is generally used for treating psoriasis in Guangdong Provincial Hospital of Chinese Medicine and has been registered (registration number: ChiCTR-IOR-15006768) for a randomized, double-blinded and placebo-controlled clinical trial. In this study, we endeavored to confirm the therapeutic effects of PSORI-CM02 formula in imiquimod-induced psoriasis-like mice and unravel its possible mechanisms of action in vivo as well as its antiproliferative property in HaCaT cells in vitro.

It is well known that cell cycle progression mediates cell growth and proliferation and that cell cycle arrest can trigger inhibition of cell proliferation and growth (18, 19). In the current study, the effects of PSORI-CM02 on cell cycle progression was analyzed using flow cytometry, and our results indicated that PSORI-CM02 suppressed HaCaT cell growth by arresting them at the G1 phase (Figure 2B), suggesting that PSORI-CM02 formula may attenuate imiquimod-induced murine psoriasis by inhibiting HaCaT cell growth.

It has been reported that repeatedly topical use of imiquimod in mice results in the influx of various immune cells and hyperplasia of the epidermis, generating a widely used murine model of psoriasis (20). In our study, we established the same model of imiquimod-induced psoriasis and observed that PSORI-CM02...
significantly lowered the PASI scores, reduced inflammatory skin temperature, and decreased the epidermal hyperplasia and epidermal thickening compared to the vehicle group, indicating that PSORI-CM02 ameliorates imiquimod-induced murine psoriasis.

We also attempted to reveal the mechanisms underlying the therapeutic effects of PSORI-CM02 on psoriasis. Production of reactive oxygen species (ROS) and weakened antioxidant system take a vital part in the pathogenesis and development of this intractable disease (21). Increased ROS production primarily affects the essential molecules in cells, such as DNA, lipid, protein, and carbohydrate. A balance between antioxidants, including SOD, CAT, and GSH, and oxidants, such as MDA, in normal skin is maintained. Malfunction of the antioxidative system and an increased production of ROS may result in skin diseases, including psoriasis (22–24). In our study, the antioxidative activities of SOD, CAT, and GSH were much lower in imiquimod-treated psoriatic skin than in normal skin whereas the level of oxidative MDA in the psoriatic skin was increased compared to that in the normal skin, which was consistent with the oxidative/antioxidative case of patients with psoriasis (25, 26). Treatments with PSORI-CM02 significantly increased the activities of these antioxidants, including SOD, CAT, and GSH, while decreasing the level of oxidant MDA. Therefore, PSORI-CM02 likely possesses a significant antioxidative feature, resulting in reduced free radical stress and subdued oxidative damage.

Excessive proinflammatory cytokines, such as TNF-α and IL-6, play a key role in the pathogenesis and progress of psoriasis. TNF-α released by multiple types of cells, including activated macrophages, dendritic cells, Th1/Th17 cells, cytotoxic T cells and adipocytes (27, 28), in the serum of patients with psoriasis is essential for the progression of psoriasis (29). It not only activates dendritic cells via NF-κB signaling, but also induces expression of adhesion molecules, angiogenic VEGF and other proinflammatory cytokines (30, 31), leading to cell proliferation and inflammation. On the other hand, IL-6 recruits neutrophils (32) and promotes the proliferation of keratinocytes in

![FIGURE 6 | PSORI-CM02 induces CD4+ Foxp3+ regulatory T cells (Tregs) in imiquimod (IMQ)-induced psoriasis-like mice. Effects of PSORI-CM02 on CD4+Foxp3+ Treg frequency in spleens and lymph nodes of IMQ-induced psoriasis-like mice were observed. Spleen and lymph node cells were isolated from IMQ-induced psoriasis-like mice seven days after treatments with PSORI-CM02 or dexamethasone acetate (DXM). To quantify CD4+ Foxp3+ Tregs, cells were stained for CD4 surface and intracellular Foxp3 makers (A) and CD4+ Foxp3+ Treg frequency in spleen and lymph node were shown (B). Data shown are the mean values ± SD (n = 6, ***P < 0.01 vs. control group, and ##P < 0.01 vs. vehicle group).]
imiquimod-induced psoriasis-like murine skin (33). In the serum of patients with psoriasis, the level of IL-6 is highly elevated (34). Thus, anti-IL-6 mAb has been proposed to be a novel therapeutic option for the treatment of psoriasis (35).

IL-23/IL-17 axis plays a central role in the development of various autoimmune diseases, including human psoriasis and imiquimod-induced murine psoriasis (20, 36). The number of IL-17-producing cells is elevated in mice topically administered with imiquimod (20, 37, 38). Th17 cells are proposed to be a cardinal source of IL-17 family cytokines, and IL-17 has been deemed as a critical cytokine for the establishment and maintenance of the psoriatic phenotype (39). It promotes inflammation via binding the receptor located on keratinocytes, dendritic cells, dermal fibroblasts, and endothelial cells (40). Our results also indicate that PSORI-CM02 ameliorates murine psoriasis by reducing IL-17 production.

NF-κB is a key inflammatory signaling pathway and a critical mediator contributing to the pathogenesis and progression of psoriasis (41, 42). NF-κB signaling alters functional states of keratinocytes and immune cells via exerting its effects on cellular proliferation, differentiation and apoptosis as well as cytokine and chemokine production (39). When keratinocytes are stimulated with TNF-α, their NF-κB signaling pathway is activated, resulting in the overexpression and release of various proinflammatory cytokines, chemokines and enzymes (43). In our present work, we found that PSORI-CM02 significantly suppressed the expression of NF-κB and IKKα in the skin of imiquimod-simulated psoriatic mice. Thus, PSORI-CM02 exerted its therapeutic effects on murine psoriasis by inhibiting NF-κB signaling pathway.

It has been reported that the imbalance between Tregs and Th17 cells is critical for the pathogenesis and development of psoriasis (44). Tregs are essential for the immune homeostasis and tolerance because of their capability of inhibiting the function of other immune cells and inflammatory responses (45). Therefore, we quantified CD4+ Foxp3+ Tregs in spleens and lymph nodes of psoriasis-like mice in vivo and determined the effects of PSORI-CM02 on CD4+ CD25+ Treg proliferation in vitro. Our results demonstrated that PSORI-CM02 upregulated the frequency of CD4+ Foxp3+ Tregs in vivo and promoted in vitro proliferation of CD4+ CD25+ Tregs as well, indicating that these Tregs play a role in attenuation of murine psoriasis by PSORI-CM02. On the other hand, previous studies by Di et al. demonstrated that astilbin ameliorated the inflammation in imiquimod-induced psoriasis-like mice via suppressing Th17 cell differentiation and IL-17 secretion (16). In our study, we found that astilbin was one of the main ingredients in PSORI-CM02 formula, and that PSORI-CM02 could inhibit the expression and production of IL-17, which was partially consistent with their studies on astilbin. However, we found that PSORI-CM02 also increased Tregs in vitro and in vivo and suppressed the expression of NF-κB and IKKα. PSORI-CM02 formula was composed of numerous chemical compositions with 18 major compositions identified already. The therapeutic
effect of PSORI-CM02 could be stronger than that of astilbin alone. In conclusion, we demonstrated that PSORI-CM02 inhibited the keratinocyte proliferation through arresting HaCaT cells at G1 phase. In addition, we found that PSORI-CM02 effectively protected imiquimod-induced psoriasis-like mice from skin lesions by decreasing TNF-α, IL-6, and IL-17 levels, regulating the oxidant/antioxidant status, altering the balance between Th17 response and CD4+ Foxp3+ Treg generation, and inhibiting NF-κB signaling pathway.

ETHICS STATEMENT

This study was carried out in accordance with the recommendations of Chinese national guidelines and institutional review board of Guangdong Provincial Academy of Chinese Medical Sciences. The protocol was approved by the Institutional Animal Care and Use Committee of Guangdong Provincial Academy of Chinese Medical Sciences.

AUTHOR CONTRIBUTIONS

Conceived and designed the experiments: CL, ZD, and LH. Performed the experiments: HC, HL, MW, WY, and XL. Analyzed and interpreted the data: HC, YY, and HZ. Revised the article: HC, HL, and ZD. All authors have read and approved the manuscript.

REFERENCES

1. Chorachoo J, Saeloh D, Srichana T, Annuaikit T, Musthafa KS, Sretirirutchai S, et al. Rhodomyrtone as a potential anti-proliferative and apoptosis inducing agent in HaCaT keratinocyte cells. Eur J Pharmacol (2016) 772:144–51. doi:10.1016/j.ejphar.2015.12.005
2. Tian S, Krueger JG, Li K, Jabbari A, Brodmerkel C, Lowes MA, et al. Meta-analysis derived (MAD) transcriptome of psoriasis defines the “core” pathogenesis of disease. PLoS One (2012) 7(9):
3. Ryan C, Kirby B. Psoriasis is a systemic disease with multiple cardiovascular and metabolic comorbidities. Dermatol Clin (2015) 33(1):41–55. doi:10.1016/j.det.2014.09.004
4. Traub M, Marshall K. Psoriasis – pathophysiology, conventional, and alternative approaches to treatment. Altern Med Rev (2007) 12(4):319–30.
5. Feldman SR, Burudpakdee C, Gala S, Nanavaty M, Mallya UG. The economic burden of psoriasis: a systematic literature review. Expert Rev Pharmacoeconomics Outcomes Res (2014) 14(5):685–705. doi:10.1586/14737167.2014.933671
6. Vuorela P, Leinonem M, Saikku P, Tammeela P, Rauhald JP, Winnenberg T, et al. Natural products in the process of finding new drug candidates. Curr Med Chem (2004) 11(11):1375–89. doi:10.2174/0929867043435116
7. Yu JJ, Zhang CS, Zhang AL, May B, Xue CC, Lu C. Add-on effect of Chinese herbal medicine bath to phototherapy for psoriasis vulgaris: a systematic review. Evid Based Complement Alternat Med (2013) 2013:673078. doi:10.1155/2013/673078
8. Zhang CS, Yu JJ, Parker S, Zhang AL, May B, Lu C, et al. Oral Chinese herbal medicine combined with pharmacotherapy for psoriasis vulgaris: a systematic review. Int J Dermatol (2014) 53(11):1305–18. doi:10.1111/ijd.12607
9. Yu JJ, Zhang CS, Coyle ME, Du Y, Zhang AL, Guo X, et al. Compound glycyrrhizin plus conventional therapy for psoriasis vulgaris: a systematic review and meta-analysis of randomized controlled trials. Curr Med Res Opin (2017) 33(2):279–87. doi:10.1080/03007995.2016.1254605
10. Zhang CS, May B, Yan Y, Yu JJ, Yao D, Chang S, et al. Terms referring to psoriasis vulgaris in the classical Chinese medicine literature: a systematic analysis. Complement Ther Med (2016) 25:55–60. doi:10.1016/j.ctm.2015.12.014
11. Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med (2009) 360(5):496–509. doi:10.1056/NEJMra0804459
12. Xiao C, Zhu Z, Sun S, Gao J, Fu M, Liu Y, et al. Activation of Langerhans cells promotes the inflammation in imiquimod-induced psoriasis-like dermatitis. J Dermatol Sci (2017) 85(3):170–7. doi:10.1016/j.jdermsci.2016.12.003
13. Chen S, Han K, Li H, Cen J, Yang Y, Wu H, et al. Isogarcinol extracted from Garcinia mangostana L. ameliorates imiquimod-induced psoriasis-like skin lesions in mice. J Agric Food Chem (2017) 65(4):846–57. doi:10.1021/acs.jafc.6b05207
14. Ise WP, Che CT, Liu K, Lin ZX. Evaluation of the anti-proliferative properties of selected psoriasis-treating Chinese medicines on cultured HaCaT cells. J Ethnopharmacol (2008) 108(1):133–41. doi:10.1016/j.jep.2006.04.023
15. Zhang S, Liu X, Mei L, Wang H, Fang F. Epigallocatechin-3-gallate (EGCG) inhibits imiquimod-induced psoriasis-like inflammation of BALB/c mice. BMC Complement Altern Med (2016) 16(1):334. doi:10.1186/s12906-016-1235-4
16. Di TT, Ruan ZT, Zhao JX, Wang Y, Liu X, Wang Y, et al. Astilbin inhibits Th17 cell differentiation and ameliorates imiquimod-induced psoriasis-like skin lesions in BALB/c mice via Jak3/Stat3 signaling pathway. Immunopharmacol (2016) 32:32–8. doi:10.1016/j.intimp.2015.12.035
17. Wen J, Pei H, Wang X, Xie C, Li S, Huang L, et al. Gambogic acid exhibits anti-psoriatic efficacy through inhibition of angiogenesis and inflammation. J Dermatol Sci (2014) 74(3):242–50. doi:10.1016/j.jdermsci.2014.03.001

FUNDING

This work was supported by grants from the Chinese Medicinal Scientific Research Project of Guangdong Province (no. 20161096), Chinese Medicinal Scientific Research and Technology Research Projects of Guangdong Provincial Hospital of Chinese Medicine and the Key Discipline Construction Projects of Integrative Medicine of High Level University of Guangdong Province (nos. YN2015QN05, YN2015MS20, and YN2016ZD01), Science and Technology Planning Project of Guangdong Province (nos. S201530011515 and 2017A050506041), Natural Science Foundation of Guangdong Province (nos. S201303011207 and 2017A030310124), Traditional Chinese Medicine Clinical Research Base of China (no. JDZX2015196), and China Postdoctoral Science Foundation (2016M600649 and 2017T100622).

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at http://www.frontiersin.org/articles/10.3389/fimmu.2017.01767/full#supplementary-material.

FIGURE S1 | FoxP3+ regulatory T cell phenotypes. Spleen cells from imiquimod-induced psoriatic mice were stained for CD4, CD25 and FoxP3 and analyzed via FACS. Only ~94% of CD4+ CD25+ T cells were FoxP3-positive in imiquimod-induced psoriatic mice.

FIGURE S2 | UHPLC profiling of PSORI-CM02. Eighteen major chemical compositions in PSORI-CM02 formula, including citric acid, gallic acid, 5-hydroxymethylfurfural and protocatechuic acid etc., were detected via UHPLC analysis. The results also showed that PSORI-CM02 did not contain conventional immunosuppressive agents cyclosporine and rapamycin.

SUPPLEMENTARY MATERIAL
18. Pu L, Amoscato AA, Bier ME, Lazo JS. Dual G1 and G2 phase inhibition by a novel, selective Cdc25 inhibitor 6-chloro-7-[corrected](2-morpholin-4-yl)ethylamino)-quinoline-5,8-dione. J Biol Chem (2002) 277(49):46877–85. doi:10.1074/jbc.M207902200

19. Chao JJ, Kuo PC, Hsu TS. Down-regulation of survivin in nitric oxide-induced cell growth inhibition and apoptosis of the human lung carcinoma cells. J Biol Chem (2004) 279(19):20267–76. doi:10.1074/jbc.M312381200

20. van der Fits L, Mourits S, Voerman JS, Kant M, Boon L, Laman JD, et al. TNF-mediated inflammatory disease. J Invest Dermatol (2013) 133(2):441–51. doi:10.1038/jid.2012.318

21. Popov I, Lewin G. A deficient function of the antioxidative system of the organism as an aetiopathogenetic factor in psoriasis. Med Hypotheses (1991) 35(3):229–36. doi:10.1016/0306-9877(91)90238-T

22. Zhou Q, Mrowietz U, Rostami-Yazdi M. Oxidative stress in the pathogenesis of psoriasis. Free Radic Biol Med (2009) 47(7):891–905. doi:10.1016/j.freeradbiomed.2009.06.033

23. Pastore S, Korkina L. Redox imbalance in T cell-mediated skin diseases. Mediators Inflamm (2010) 2010:861949. doi:10.1155/2010/861949

24. Geronikaki AA, Gavalas AM. Antioxidants and inflammatory disease: synthetic and natural antioxidants with anti-inflammatory activity. Comb Chem High Throughput Screen (2006) 9(6):425–42. doi:10.2174/1386207067698481

25. Baz K, Cimen MY, Kokturk A, Yazici AC, Eskandari G, Ikioglu G, et al. Oxidant/antioxidant status in patients with psoriasis. Vespis Med J (2003) 44(6):987–90. doi:10.3349/vmj.2003.44.6.987

26. Pujari VM, Suryakar AN, Ireddy S. Oxidants and antioxidant status in psoriasis patients. Biomed Res (2011)

12(2):221–24.

27. Gottlieb AB, Chaiman F, Masud S, Cardinale I, Abello MV, Lowes MA, et al. TNF inhibition rapidly down-regulates multiple proinflammatory pathways in psoriasis plaques. J Immunol (2005) 175(4):2721–9. doi:10.4049/jimmunol.175.4.2721

28. Aggarwal BB, Gupta SC, Sung B. Curcumin: an orally bioavailable blocker of TNF and other pro-inflammatory biomarkers. Br J Pharmacol (2013) 169(8):1672–92. doi:10.1111/bph.12131

29. Fantuzzi F, Del Giglio M, Gisondi P, Girolomoni G. Targeting tumor necrosis factor alpha in psoriasis and psoriatic arthritis. Expert Opin Ther Targets (2013) 175(4):2721–9. doi:10.1016/j.eop.2013.01.002

30. Kupetsky EA, Mathers AR, Ferris LK. Anti-cytokine therapy in the treatment of psoriasis. Cytokine (2013) 61(3):704–12. doi:10.1016/j.cyto.2012.12.027

31. Bradley JR. TNF-mediated inflammatory disease. J Pathol (2008) 214(2):149–60. doi:10.1002/path.2287

32. Fielding CA, McLoughlin RM, McLeod L, Colmont CS, Najdovska M, Grail D, et al. IL-6 regulates neutrophil trafficking during acute inflammation via STAT3. J Immunol (2008) 181(3):2189–95. doi:10.4049/jimmunol.181.3.2189

33. Grossman RM, Kuebler J, Yourish D, Granelli-Piperno A, Murphy DP, May LT, et al. Interleukin 6 is expressed in high levels in psoriatic skin and stimulates proliferation of cultured human keratinocytes. Proc Natl Acad Sci U S A (1989) 86(16):6367–71. doi:10.1073/pnas.86.16.6367

34. Toruniowa B, Krassowska D, Kozioł M, Książek A, Pietrzak A. Serum levels of IL-6 in mycosis fungoides, psoriasis, and lichen planus. Ann N Y Acad Sci (1995) 762:432–4. doi:10.1111/j.1749-6632.1995.tb2358.x

35. Saggini A, Chimenti S, Chiricozzi A. IL-6 as a druggable target in psoriasis: focus on putustular variants. J Immunol Res (2014) 2014:964069. doi:10.1155/2014/964069

36. Di Cesare A, Di Meglio P, Nestle FO. The IL-23/Th17 axis in the immunopathogenesis of psoriasis. J Invest Dermatol (2009) 129(6):1339–50. doi:10.1038/jid.2009.59

37. Cai Y, Shen X, Ding C, Qi C, Li K, Li X, et al. Pivotal role of dermal IL-17-producing gammadelta T cells in skin inflammation. Immunity (2011) 35(4):596–610. doi:10.1016/j.immuni.2011.08.001

38. El Malki K, Karbach SH, Huppert J, Zayoud M, Reissig S, Schuler R, et al. An alternative pathway of imiquimod-induced psoriasis-like skin inflammation in the absence of interleukin-17 receptor a signaling. J Invest Dermatol (2013) 133(2):441–51. doi:10.1038/jid.2012.318

39. Lowes MA, Suarez-Farinas M, Krueger JG. Immunology of psoriasis. Annu Rev Immunol (2014) 32:227–55. doi:10.1146/annurev-immunol-032713-120225

40. Lynde CW, Poulin Y, Vender R, Bourcier M, Khalil S, Interleukin 17A: toward a new understanding of psoriasis pathogenesis. J Am Acad Dermatol (2014) 71(1):141–50. doi:10.1016/j.jaad.2013.12.036

41. Nair RF, Duffin KC, Helms C, Ding J, Stuart PE, Goldgar D, et al. Genome-wide scan reveals association of psoriasis with IL-23 and NF-kappaB pathways. Nat Genet (2010) 42(6):483–7. doi:10.1038/ng.802

42. Goldminz AM, Au SC, Kim N, Gottlieb AB, Lizzul PF. NF-kappaB: an essential transcription factor in psoriasis. J Dermatol Sci (2013) 69(2):89–94. doi:10.1016/j.jdermsci.2012.11.002

43. Tsuruta D. NF-kappaB links keratinocytes and lymphocytes in the pathogenesis of psoriasis. Recent Pat Inflamm Allergy Drug Discov (2009) 3(1):40–8. doi:10.2174/187221309787158399

44. Mattozzi C, Salvi M, D’Epro S, Giancristoforo S, Macaluso L, Luca C, et al. Importance of regulatory T cells in the pathogenesis of psoriasis: review of the literature. Dermatology (2013) 227(2):134–45. doi:10.1159/000353398

45. Bovenschen HJ, van de Kerkhof PC, van Erp PE, Woestenenk R, Joosten I, Koenen HJ, Foxp3+ regulatory T cells of psoriasis patients easily differentiate into IL-17A-producing cells and are found in lesional skin. J Invest Dermatol (2011) 131(9):1853–60. doi:10.1038/jid.2011.139

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.